A simple and general strategy for postsurgical personalized cancer vaccine therapy based on an injectable dynamic...

Area of Science:

• Oncology
• Immunology
• Biomaterials Science

Background:

• Cancer vaccines aim to stimulate immune responses against tumors, but progress is hindered by challenges in identifying tumor-specific antigens.
• Surgery is a primary cancer treatment, creating an opportunity to utilize resected tumor tissue for therapeutic development.

Purpose of the Study:

• To evaluate the feasibility of using resected tumor tissue as a source of antigens for personalized cancer vaccine development.
• To design and assess a novel dynamic covalent hydrogel-based vaccine (DCHVax) for postsurgical cancer management.

Main Methods:

• Proteins extracted from resected tumors were used as antigens.
• A dynamic covalent hydrogel matrix composed of multi-armed poly(ethylene glycol) (8-arm PEG) and oxidized dextran (ODEX) was employed.
• CpG was used as an adjuvant to enhance immune stimulation.

Main Results:

• Subcutaneous injection of DCHVax successfully recruited dendritic cells to the hydrogel matrix *in situ*.
• The DCHVax formulation elicited robust tumor-specific immune responses.
• Significant inhibition of postoperative residual tumor growth was observed in multiple murine tumor models.

Conclusions:

• A simple and personalized method for developing cancer vaccines using resected tumor antigens has been established.
• The DCHVax strategy shows promise for effective postsurgical cancer treatment by leveraging *in situ* immune stimulation.
• This approach offers a potentially clinically relevant strategy for improving postoperative cancer management and patient outcomes.